TheraRadar
← Back
Data updated: Sep 20, 2026

J MOLNER

Specialty

J MOLNER is a specialty pharmaceutical company focused on Neurology, Infectious Disease, Dermatology.

1984
Since
12
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

J MOLNER's Key Drugs

J MOLNER's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

J MOLNER's Recent FDA Approvals

New NDA/BLA approvals for J MOLNER over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

J MOLNER's Therapeutic Areas

J MOLNER's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 33%
2 drugs
Infectious Disease 17%
1 drugs
Dermatology 17%
1 drugs
Cardiovascular 17%
1 drugs
Ophthalmology 17%
1 drugs

J MOLNER Pipeline Snapshot

Active clinical trials for J MOLNER across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling